IndexBox: Human IFN-γ ELISA Kit Market Forecast for 2035, with Growth Driven by Immuno-Oncology Demand

The IndexBox report forecasts a 6.2% compound annual growth rate for the human IFN-γ ELISA kit market from 2026 to 2035, with the market index reaching 182 in 2035 (2025=100). Growth is driven primarily by demand for IFN-γ as a pharmacodynamic biomarker in immuno-oncology research, requirements for GMP-grade kits in cell and gene therapy manufacturing, and diagnosis of infectious diseases such as tuberculosis. Asia-Pacific will contribute the largest increase in demand, while North America and Europe will grow more moderately.